Landos Biopharma

Landos Biopharma: Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first in target new MOA, oral therapeutics for autoimmune diseases, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Lead asset omilancor is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway (UC Ph2 complete in 2021, initiating Ph3 in 2H21, Crohn's Ph2 initiated 1H21). NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway (UC Ph1b initiated 2Q21). Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. Partnership with LianBio to develop and commercialize Omilancor and NX-13 in greater China and select Asian markets announced May 2021.
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Gastrointestinal, Metabolic Disorders
Public, USA
Market Cap
100MM - 500MM
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Company Participants at Private Company Showcase NYC 2019

  • Josep Bassaganya-Riera, Chairman of the Board, President & CEO

Upcoming Company Event Participation

Lead Programs


Indication Phase


Indication Phase


Indication Phase
LANCL2 Pre-clinical
LANCL2 Pre-clinical

Top 10 Holders of Landos Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Perceptive Advisors LLC 45.86 17,960,839 198.29 Stakes 3/31/21
RTW Investments LP 10.92 4,275,722 47.20 13F 3/31/21
Logos Global Management LP 1.87 734,000 8.10 13F 3/31/21
OrbiMed Advisors LLC 1.74 681,000 7.52 13F 3/31/21
Deerfield Management Company LP 1.15 450,000 4.97 13F 3/31/21
JPMorgan Investment Management, Inc. 0.87 340,473 3.76 13F 3/31/21
The Vanguard Group, Inc. 0.76 303,518 3.35 Funds 6/30/21
Woodline Partners LP 0.54 213,335 2.36 13F 3/31/21
Vanguard Group, Inc. (Subfiler) 0.45 176,409 1.95 13F 3/31/21
BlackRock Fund Advisors 0.45 175,260 1.93 13F 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.